Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins

Abstract

There are several therapeutic antibodies being developed targeting glycanbinding proteins, including CD22, CD33, DEC-205, and CD62P, for different diseases. The clinical investigations demonstrated benefits of treatments with one antibody-drug conjugate against CD22 being approved by the regulatory agencies. The recent progresses in clinical developments of these antibodies have provided great promises in therapeutic targeting of more glycan-binding proteins for treating multiple diseases, including inflammation, autoimmune diseases, and hematological malignancies.

Native size-exclusion chromatography-mass spectrometry: suitability for antibody–drug conjugate drug-to-antibody ratio quantitation across a range of chemotypes and drug-loading levels

“…Other conjugation strategies involve homogeneous sitespecific attachment of drug-linkers by strategically modifying the primary sequence by inserting unpaired cysteine residues or enzymatic motifs into the primary sequence. [12][13][14][15] The potency of an ADC is determined in large part by the average number of drugs attached to the mAb, i.e., the drug-toantibody ratio (DAR). 16 Consequently, key assays for measuring DAR should be developed and optimized as soon as possible in preclinical development.…”

Novel Reversible Fluorescent Glycan Linker for Functional Glycomics

“…Beyond their roles in energy storage and structural support, glycans via their interactions with glycan-binding proteins (GBPs) are important in numerous physiological and pathological processes, such as platelet clearance, cellular adhesion and migration, innate immune responses, fertilization, embryogenesis, pathogen infection, inflammation, and the development of autoimmune diseases and cancer . Therefore, more and more therapeutic agents and diagnostic tools targeting on glycan–GBP interactions are under development. − Despite its well-recognized importance, glycomics, the structures and functions of glycans in biological systems, has lagged far behind genomics, transcriptomics, and proteomics. This lag is mainly due to the unique structural complexity of glycans, the nontemplate driven synthesis of glycans, and the indirect regulation of glycan synthesis by genes, which create unique technical challenges for glycan sequencing and synthesis, thereby hindering access to complex glycans for functional studies.…”